2026-09-11Screening report
Data as of 2026-09-11US market
Summary
September 11, 2026 screening identifies extreme valuation dislocations in Adobe, Cooper Companies, DexCom, Amgen, and Intel.
Screening weights
Fundamental improvement25%
Candidate comparison
| Rank | Ticker | Sector | 3M return | Revenue YoY | OPM Δ | FCF | Score |
|---|
| 1 | Adobe | Technology | -12.4% | +10.6% | +1.2%p | Positive | 9.1 |
| 2 | Cooper Companies | Healthcare | -18.2% | +7.5% | +1.1%p | Positive | 8.9 |
| 3 | DexCom | Healthcare | -21.8% | +15.3% | +1.8%p | Positive | 8.8 |
| 4 | Amgen | Healthcare | -7.1% | +10.0% | +1.2%p | Positive | 8.7 |
| 5 | Intel | Technology | -14.2% | +7.5% | +0.6%p | Positive | 8.4 |
| 6 | Pinterest | Communication | -14.8% | +21.0% | +3.4%p | Positive | 8.3 |
| 7 | Expedia | Consumer | -9.2% | +6.2% | +1.5%p | Positive | 8.2 |
| 8 | Salesforce | Technology | -7.4% | +8.4% | +2.4%p | Positive | 8.1 |
| 9 | Lululemon | Consumer | -14.6% | +9.8% | +0.8%p | Positive | 8.0 |
| 10 | Snowflake | Technology | -12.9% | +29.1% | +3.2%p | Positive | 7.8 |
Screened names (observations)
Observation
Dropped to multi-year valuation low ($248) post-earnings despite Q3 record revenue and EPS b
Catalysts to watch
- Enterprise Firefly and GenStudio contract acceleration
- Aggressive $8B+ share repurchase program execution
Risks
- Generative AI tool pricing competition from OpenAI
Framework exit signals
- Digital Media net new ARR growth decelerates below +8% YoY
Metrics to watch
- Digital Media ARR net additions
- Non-GAAP operating margin
Observation
Extreme oversold RSI < 25 after distributor destocking sell-off; 66% gross margin and contac
Catalysts to watch
- Americas optical distributor inventory normalization
- MyDay daily toric and multifocal lens global adoption
Risks
- Extended optical channel destocking into Q4
Framework exit signals
- CooperVision constant-currency organic growth falls below +3%
Metrics to watch
- CooperVision constant-currency revenue
- Gross profit margin
Observation
RSI under 26 on persistent rebate noise; core revenue expanded +15.3% YoY with +1.8%p operat
Catalysts to watch
- Stelo OTC biosensor retail volume expansion
- Commercial payer coverage for non-insulin Type 2 diabetics
Risks
- Rebate structure pressure in US pharmacy channels
Framework exit signals
- G7 sensor volume growth drops below +10% YoY
Metrics to watch
- G7 sensor volume growth
- Stelo OTC adoption rate
Observation
Deep value following recent sell-off on competitor trial noise; trading at multi-year discoun
Catalysts to watch
- MariTide Phase 2 obesity data readouts
- Double-digit volume growth in Repatha and Tezspire
Risks
- GLP-1 obesity trial disclosures by competitors
Framework exit signals
- MariTide development safety discontinuation
Metrics to watch
- MariTide Phase 2 trial updates
- Core product volume growth
Observation
Fell -4.5% on broker downgrade and capex noise to major technical support; multi-year turnar
Catalysts to watch
- Intel 18A node volume manufacturing customer milestones
- Server CPU market share stabilization with Granite Rapids
Risks
- Foundry operating loss ramp timeline
Framework exit signals
- Intel 18A high-volume manufacturing delays beyond 2026
Metrics to watch
- IFS external customer commitments
- Data Center & AI segment margin
AlphaSignal: Top 5 Oversold US Stocks Poised for Rebound (Sep 11, 2026)
1. Executive Summary
- Date: September 11, 2026 | Market: US Equities (S&P 500 / Russell 1000)
- Overview: While August Core CPI dropped to a 64-month low sparking broader relief, earnings dislocations and sector downgrades created prime oversold dip-buying opportunities in cash-rich compounders.
- Criteria: Daily drop / RSI < 30, expanding revenue & OPM, positive FCF, solid balance sheet.
2. Candidate Comparison Table
- ADBE (9.1) - Technology | 3M: -12.4% | Rev: +10.6% | OPM: +1.2%p | FCF: Positive
- COO (8.9) - Healthcare | 3M: -18.2% | Rev: +7.5% | OPM: +1.1%p | FCF: Positive
- DXCM (8.8) - Healthcare | 3M: -21.8% | Rev: +15.3% | OPM: +1.8%p | FCF: Positive
- AMGN (8.7) - Healthcare | 3M: -7.1% | Rev: +10.0% | OPM: +1.2%p | FCF: $10.5B
- INTC (8.4) - Technology | 3M: -14.2% | Rev: +7.5% | OPM: +0.6%p | FCF: Positive
- PINS (8.3) | 7. EXPE (8.2) | 8. CRM (8.1) | 9. LULU (8.0) | 10. SNOW (7.8)
3. Final Top 5 Recommendations
- ADBE (Adobe): Slipped to multi-year low ($248) despite Q3 beat; 46% Non-GAAP OPM, $8B+ FCF, enterprise Firefly growth.
- COO (Cooper Companies): RSI < 25 post-earnings on distributor destocking noise; 66% gross margin, 46% discount to fair value.
- DXCM (DexCom): Deep oversold RSI < 26 on transitory rebate noise; +15.3% rev, expanding OPM, Stelo OTC expansion.
- AMGN (Amgen): Historic selloff overreaction floor; $10.5B annual FCF, 3.1% dividend yield margin of safety.
- INTC (Intel): Downgrade overreaction (-4.5%) to key support; 18A node execution and server chip stabilization catalysts.
4. Conclusion
- Highest Conviction: ADBE | Deepest Dislocation: COO | Extreme Oversold: DXCM | Defensive Yield: AMGN | Turnaround: INTC
- Watchlist: PINS, EXPE, CRM, LULU, SNOW
Not investment advice. Scores and lists are relative snapshots.
← All notes